GENETIC-VARIATION OF HIV TYPE-1 IN 4 WORLD-HEALTH-ORGANIZATION-SPONSORED VACCINE EVALUATION SITES - GENERATION OF FUNCTIONAL ENVELOPE (GLYCOPROTEIN-160) CLONES REPRESENTATIVE OF SEQUENCE SUBTYPE-A, SUBTYPE-B, SUBTYPE-C, AND SUBTYPE-E

GENETIC-VARIATION OF HIV TYPE-1 IN 4 WORLD-HEALTH-ORGANIZATION-SPONSORED VACCINE EVALUATION SITES - GENERATION OF FUNCTIONAL ENVELOPE (GLYCOPROTEIN-160) CLONES REPRESENTATIVE OF SEQUENCE SUBTYPE-A, SUBTYPE-B, SUBTYPE-C, AND SUBTYPE-E
复制标题

DOI:
10.1089/aid.1994.10.1359
复制
发表时间:
1994-11-01
影响因子:
1.5
通讯作者:
KORBER, B
KORBER, B
中科院分区:
医学4区
文献类型:
--
作者:
GAO, F;YUE, L;KORBER, B

文献摘要

被引文献

相似文献

作为世卫组织艾滋病毒分离和鉴定网络的一部分,我们用聚合酶链式反应扩增、克隆和测序了从四个世卫组织赞助的疫苗评估地点(巴西、卢旺达、泰国和乌干达)收集的12个艾滋病毒-1分离株的gp120和gp160基因。包膜克隆来源于血清转换2年内无症状个体的PBMC培养的分离株。对他们推导的氨基酸序列的分析表明,除了一个之外,所有的基因都含有一个不间断的开放阅读框架。选择的gp160构建体的瞬时表达和生物学特性鉴定了编码全长和功能性包膜糖蛋白的6个克隆。对其核苷酸序列的系统发育分析表明,它们代表HIV-1 A、B、C和E亚型。由于目前对HIV-1包膜免疫生物学的了解几乎完全来自B亚型病毒,这些试剂应该有助于未来对更广泛的病毒的包膜结构、功能和抗原性的研究。这应有助于设计和评估有效的艾滋病毒-1疫苗。
As part of the WHO Network for HIV Isolation and Characterization, we PCR amplified, cloned, and sequenced gp120 and gp160 genes from 12 HIV-1 isolates collected in four WHO-sponsored vaccine evaluation sites (Brazil, Rwanda, Thailand, Uganda). Envelope clones were derived from PBMC-grown isolates obtained from asymptomatic individuals within 2 years of seroconversion. Analysis of their deduced amino acid sequences identified all but one to contain an uninterrupted open reading frame. Transient expression and biological characterization of selected gp160 constructs identified six clones to encode full length and functional envelope glycoproteins. Phylogenetic analysis of their nucleotide sequences revealed that they represent HIV-1 subtypes A, B, C, and E. Since current knowledge of HIV-1 envelope immunobiology is almost exclusively derived from subtype B viruses, these reagents should facilitate future envelope structure, function and antigenicity studies on a broader spectrum of viruses. This should assist in the design and evaluation of effective vaccines against HIV-1.